A Phase 1 interventional study of TAK-881 in Healthy Volunteers, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-12.
Sponsored by Takeda · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main aims of this study are to check for side effects from TAK-881 in healthy adults and to learn how much TAK-881 they can receive without getting side effects from it.
During the study, participants will receive one infusion of TAK-881 under the skin (subcutaneous infusion) on Day 1 at a lower dose level followed by participants receiving one infusion of higher dose levels with ongoing safety monitored by the doctor to ensure optimal tolerability and safety.
Participants will stay in the clinic for 4 days and will come back after 4 weeks. A follow up visit will take place 12 weeks after the TAK-881 infusion.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Participants on stable dose of hormone replacements (e.g., thyroid hormone replacement) or oral are permitted.
Participants will be excluded if abnormal hematology, chemistry, and other laboratory values are greater than (>)10% above the (ULN) or >10% below the lower limit of normal (LLN) except for liver function tests and absolute neutrophils. Participants will be excluded if any of the following laboratory parameters meet the criteria below:
Participants who, within 30 days prior to the first dose of IP:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of TAK-881 comprising of 0.4 gram per kilogram (g/kg) (in-line warmed) Immune Globulin Subcutaneous (IGSC), 20 percent (%) at progressively increased infusion rates and Recombinant Human Hyaluronidase (rHuPH20) dose of 80 unit per gram (U/g) immunoglobulin G (IgG) on Day 1 of the study treatment period.
Biological: TAK-881
Participants will receive a single dose of TAK-881 comprising of 1.0 g/kg (in-line warmed) IGSC, 20% at progressively increased infusion rates and rHuPH20 dose of 80 U/g IgG on Day 1 of the study treatment period.
Biological: TAK-881
Participants will receive a single dose of TAK-881 comprising of 1.0 g/kg (un-warmed) IGSC, 20% at progressively increased infusion rates and rHuPH20 dose of 80 U/g IgG on Day 1 of the study treatment period.
Biological: TAK-881
Participants will receive subcutaneous infusion of TAK-881 on Day 1.
Also known as: Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase.
Number of Participants With Tolerability Events Related to Infusion of TAK-881 Per Infusion Site
A tolerability event was considered to have occurred if an infusion was tolerable. An infusion was considered tolerable if the infusion rate was not reduced or the infusion was not interrupted or stopped, due to any treatment-emergent adverse event (TEAE) related to TAK-881. Number of participants with tolerability events related to infusion of TAK-881 per infusion sites (1 and 2) were reported.
Time frame: Up to Day 4
Number of Participants With TEAEs
A TEAE was defined as any event emerged or manifested at or after the initiation of treatment with an Investigational product (IP) or medicinal product or any existing event that worsened in either intensity or frequency following exposure to the IP or medicinal product. Any clinically significant treatment-emergent changes in clinical laboratory measurements and vital signs were recorded as TEAEs. Number of participants with TEAEs were reported.
Time frame: From the start of study drug administration up to Week 13
Number of Participants With Positive Binding Anti-Drug Antibodies (ADA) and Neutralizing Antibodies to rHuPH20
Positive binding ADA was defined as titer greater than or equal to (\>=) 1:160. Neutralizing antibodies were only tested if binding ADA titer was \>= 1:160. Number of participants with positive binding ADA and neutralizing antibodies to rHuPH20 were reported.
Time frame: Baseline up to Week 13
Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site
The maximum tolerable infusion rate achieved referred to the administration of IGSC, 20% at progressively increasing infusion rates and was defined as the highest infusion rate achieved at which the infusion was tolerable (i.e., no stopping, interruption, or infusion rate reduction due to a TAK-881-related TEAE). The maximum tolerable infusion rate for Infusion Site 2 depended on the planned volume according to the stepwise infusion rate escalation regimen. Number of participants who achieved maximum tolerable infusion rate per infusion sites (1 and 2) for each infusion rate (30, 60, 120, 180, and 300 milliliter per hour \[mL/hour\]) were reported.
Time frame: Day 1 up to Day 4
Total Volume Infused Per Infusion Site for rHuPH20 and IGSC
Total volume infused per infusion sites (1 and 2) for rHuPH20 and IGSC were reported.
Time frame: At Day 1
Time to Deliver the Total Infused Volume Per Infusion Site
Time to deliver (in minutes) the total infused volume was calculated as (stop date/time of IGSC 20% administration) - (start date/time of rHuPH20 administration). Time to deliver the total infused volume per infusion sites (1 and 2) were reported.
Time frame: At Day 1
This study was conducted at single center in the United States from 12 October 2021 to 12 April 2022.
| Milestone | TAK-881 0.4 g/kg Warmed | TAK-881 1.0 g/kg Warmed | TAK-881 1.0 g/kg Un-warmed |
|---|---|---|---|
| Started | 8 | 8 | 8 |
| Completed | 8 | 8 | 7 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
A tolerability event was considered to have occurred if an infusion was tolerable. An infusion was considered tolerable if the infusion rate was not reduced or the infusion was not interrupted or stopped, due to any treatment-emergent adverse event (TEAE) related to TAK-881. Number of participants with tolerability events related to infusion of TAK-881 per infusion sites (1 and 2) were reported.
| Participants | TAK-881 0.4 g/kg Warmed | TAK-881 1.0 g/kg Warmed | TAK-881 1.0 g/kg Un-warmed |
|---|---|---|---|
| Infusion Site 1 | 8 | 8 | 8 |
| Infusion Site 2 | — | 4 | 7 |
A TEAE was defined as any event emerged or manifested at or after the initiation of treatment with an Investigational product (IP) or medicinal product or any existing event that worsened in either intensity or frequency following exposure to the IP or medicinal product. Any clinically significant treatment-emergent changes in clinical laboratory measurements and vital signs were recorded as TEAEs. Number of participants with TEAEs were reported.
| Participants | TAK-881 0.4 g/kg Warmed | TAK-881 1.0 g/kg Warmed | TAK-881 1.0 g/kg Un-warmed |
|---|---|---|---|
| Number of Participants With TEAEs | 8 | 8 | 8 |
Positive binding ADA was defined as titer greater than or equal to (\>=) 1:160. Neutralizing antibodies were only tested if binding ADA titer was \>= 1:160. Number of participants with positive binding ADA and neutralizing antibodies to rHuPH20 were reported.
| Participants | TAK-881 0.4 g/kg Warmed | TAK-881 1.0 g/kg Warmed | TAK-881 1.0 g/kg Un-warmed |
|---|---|---|---|
| Binding Antibodies | 0 | 0 | 0 |
The maximum tolerable infusion rate achieved referred to the administration of IGSC, 20% at progressively increasing infusion rates and was defined as the highest infusion rate achieved at which the infusion was tolerable (i.e., no stopping, interruption, or infusion rate reduction due to a TAK-881-related TEAE). The maximum tolerable infusion rate for Infusion Site 2 depended on the planned volume according to the stepwise infusion rate escalation regimen. Number of participants who achieved maximum tolerable infusion rate per infusion sites (1 and 2) for each infusion rate (30, 60, 120, 180, and 300 milliliter per hour \[mL/hour\]) were reported.
| Participants | TAK-881 0.4 g/kg Warmed | TAK-881 1.0 g/kg Warmed | TAK-881 1.0 g/kg Un-warmed |
|---|---|---|---|
| Infusion Site 1: 30 mL/hour | 0 | 0 | 0 |
| Infusion Site 1: 60 mL/hour | 0 | 0 | 0 |
| Infusion Site 1: 120 mL/hour | 0 | 0 | 0 |
| Infusion Site 1: 180 mL/hour | 0 | 0 | 0 |
| Infusion Site 1: 300 mL/hour | 8 | 8 | 8 |
| Infusion Site 2: 30 mL/hour | — | 0 | 0 |
| Infusion Site 2: 60 mL/hour | — | 0 | 2 |
| Infusion Site 2: 120 mL/hour | — | 0 | 1 |
| Infusion Site 2: 180 mL/hour | — | 1 | 1 |
| Infusion Site 2: 300 mL/hour | — | 3 | 3 |
Total volume infused per infusion sites (1 and 2) for rHuPH20 and IGSC were reported.
| milliliter (mL) | TAK-881 0.4 g/kg Warmed | TAK-881 1.0 g/kg Warmed | TAK-881 1.0 g/kg Un-warmed |
|---|---|---|---|
| rHuPH20: Infusion Site 1 | 14.3 ± 1.28 | 29.3 ± 1.39 | 29.4 ± 1.77 |
| rHuPH20: Infusion Site 2 | — | 10.0 ± 5.16 | 7.3 ± 6.16 |
| IGSC 20%: Infusion Site 1 | 141.3 ± 13.30 | 291.3 ± 14.33 | 293.8 ± 17.68 |
| IGSC 20%: Infusion Site 2 | — | 97.5 ± 51.72 | 70.0 ± 61.64 |
Time to deliver (in minutes) the total infused volume was calculated as (stop date/time of IGSC 20% administration) - (start date/time of rHuPH20 administration). Time to deliver the total infused volume per infusion sites (1 and 2) were reported.
| minute | TAK-881 0.4 g/kg Warmed | TAK-881 1.0 g/kg Warmed | TAK-881 1.0 g/kg Un-warmed |
|---|---|---|---|
| Infusion Site 1 | 63.5 (59 to 74) | 99.5 (92 to 103) | 102.0 (91 to 112) |
| Infusion Site 2 | — | 53.0 (35 to 68) | 41.0 (22 to 69) |
Collected over From the start of study drug administration up to Week 13. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TAK-881 0.4 g/kg Warmed | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| TAK-881 1.0 g/kg Warmed | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| TAK-881 1.0 g/kg Un-warmed | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Event | TAK-881 0.4 g/kg Warmed | TAK-881 1.0 g/kg Warmed | TAK-881 1.0 g/kg Un-warmed |
|---|---|---|---|
| Infusion site erythemaGeneral disorders | 8/8 | 8/8 | 8/8 |
| Infusion site swellingGeneral disorders | 7/8 | 8/8 | 8/8 |
| Infusion site painGeneral disorders | 4/8 | 5/8 | 4/8 |
| Infusion site pruritusGeneral disorders | 3/8 | 5/8 | 5/8 |
| DiarrhoeaGastrointestinal disorders | 1/8 | 0/8 | 0/8 |
| DizzinessNervous system disorders | 0/8 | 0/8 | 1/8 |
| HeadacheNervous system disorders | 1/8 | 0/8 | 1/8 |
| Infusion site extravasationGeneral disorders | 1/8 | 0/8 | 0/8 |
| NauseaGastrointestinal disorders | 1/8 | 0/8 | 0/8 |
Safety set included all participants who received a partial or a full dose of TAK-881.
| Age, Continuous(years) | TAK-881 0.4 g/kg Warmed | TAK-881 1.0 g/kg Warmed | TAK-881 1.0 g/kg Un-warmed | Total |
|---|---|---|---|---|
| Mean | 42.6 ± 4.57 | 39.4 ± 4.10 | 34.9 ± 10.12 | 39.0 ± 7.29 |
| Sex: Female, Male(Participants) | TAK-881 0.4 g/kg Warmed | TAK-881 1.0 g/kg Warmed | TAK-881 1.0 g/kg Un-warmed | Total |
|---|---|---|---|---|
| Female | 5 | 2 | 4 | 11 |
| Male | 3 | 6 | 4 | 13 |
| Ethnicity (NIH/OMB)(Participants) | TAK-881 0.4 g/kg Warmed | TAK-881 1.0 g/kg Warmed | TAK-881 1.0 g/kg Un-warmed | Total |
|---|---|---|---|---|
| Hispanic or Latino | 8 | 7 | 8 | 23 |
| Not Hispanic or Latino | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | TAK-881 0.4 g/kg Warmed | TAK-881 1.0 g/kg Warmed | TAK-881 1.0 g/kg Un-warmed | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 1 |
| White | 8 | 7 | 8 | 23 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Oct 2021 to primary completion in Apr 2022, 6 months.
Results were first posted in Jan 2024, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.